期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 52, 期 2, 页码 369-378出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm801044g
关键词
-
Cannabinoid receptor 2 (CB2 receptor) ligands are potential candidates for the therapy of chronic pain, inflammatory disorders, atherosclerosis, and osteoporosis. We describe the development of pharmacophore models for CB2 receptor ligands, as well as a pharmacophore-based virtual screening workflow, which resulted in 14 hits for experimental follow-up. Seven compounds were identified with K-i values below 25 mu M. The CB2 receptor-selective pyridine tetrahydrocannabinol analogue 8 (K-i = 1.78 mu M) was identified as a CB2 partial agonist. Acetamides 12 (K-i = 1.35 mu M) and 18 (K-i = 2.1 mu M) represent new scaffolds for CB2 receptor-selective antagonists and inverse agonists, respectively. Overall, our pharmacophore-based workflow yielded three novel scaffolds for the chemical development of CB2 receptor ligands.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据